Public presentation of OPAL001 and OPAL A include:
- The publication of a manuscript by Graves N & Ashby AE in Wound Practice and Research, May 2008 describing the clinical use of OPAL001 in the Quadriplegic Centre, Perth. The abstract stated:
- Treatment appeared to be effective, and persistent large and deep ulcers were healed. … The preliminary data presented show some evidence for OPAL001 therapy reducing costs and improving outcomes; the situation where costs decrease and health outcomes improve is both unusual and highly desirable for health care decision makers.
- The presentation at the biennial conference of the Australian Wound Management Association in May 2008 by Professor Geoffrey Mitchell of the University of Queensland School of Medicine describing the clinical efficacy of OPAL001 in the treatment of a variety of different ulcer types. OPAL001 is a variation of OPAL A that was trialled in the early years. A brief excerpt of the underlying report is representative of the clinical data to date:
- The story for each person was similar. The ulcers had been treated using conventional therapy for long periods of time, during which there was little or no improvement. … The temporal association between the application of the treatment and the commencement of healing is impressive. … Each patient experienced a marked improvement in his quality of life.
- The presentation of a poster at the European Wound Management Association conference in Helsinki in May 2008, describing the clinical efficacy of OPAL001 and OPAL A in the treatment of a variety of different ulcer types.
- The presentation of a poster at the conference of the Australian Wound Management Association in March 2010 by Susan Bonham & Chris Baldwin of the Quadriplegic Centre and Dr Lynette Tozer on the treatment of chronic pressure ulcers on the foot with OPAL A.
- Three papers published in Dec 2011 Wound Practice and Research (Journal of the Australian Wound management Association)
- Clinical observations supporting a vasodilatory effect of the modified papaya extract OPAL001 Mitchell GK
- Treatment of a sacral pressure ulcer and extensive hyperkeratosis with OPAL A filtrate and cream: A case study Baldwin C & Bonham S
- Effect of the novel wound healing agent, OPAL A on leukotriene B4 production in human neutrophils and 5-lipoxygenase activity Russell FD, Windegger T, Hamilton KD & Cheetham NWH
- The presentation of three posters at the biennial conference of the Australian Wound Management Association in May 2014
- Cysteine Proteases May Play a Role in the Wound Healing Properties of OPAL A Mike Philpott, Neil Rzechorzek, Geoffrey Mitchell and Michael Woodward
- Randomised, Placebo controlled Study of OPAL A for the Treatment of Chronic Venous and Pressure Ulcers Michael Woodward, Mark Woolley, Mark Richardson
- Enzymatic Debridement: A failed promise, or hope for the future? Jake Nowicki and Alex Siviour
- A session presentation by Dr Mark Baldock at the biennial conference of the Australian Wound Management Association in May 2014.
- Optiderma OPAL A. For the preventative treatment and management of chronic wounds for Aged Care providers. A model for change